If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  AUA: Investigative Drug, Cialis, Outperforms Placebo For Erectile Dysfunction By Ed Susman Special to DG News
ANAHEIM, CA -- June 6, 2001 -- Cialis, an experimental treatment for erectile dysfunction, appears to allow men to achieve successful intercourse about 75 percent of the time over the course of 24 hours, researchers said at the 96th annual meeting of the American Urological Association. The study was presented by lead author, Dr. Harin Padma-Nathan, professor of urology at the Keck School of Medicine of the University of Southern California, Beverly Hills, California. Dr. Padma-Nathan said that in studies that scrutinized the responsiveness of the 284 men who enrolled in the trials, he found that a successful intercourse rate of 75 percent was consistent throughout the 24 hours after taking a 25 mg dose of Cialis during an eight-week at-home trial. That response rate adds a degree of spontaneity to the act of intercourse among couples. In doctors’ office studies, men on Cialis were able to have more clinically significant erections at 45 minutes on the 10 mg dose than were patients taking placebo. The 20 mg dose allows patients to achieved erections as early as 16 minutes after taking a dose of medication, and 80 percent were able to achieve erections at 30 minutes. The drug was well-tolerated in both the 61-patient pilot study and the 223- patient efficacy study. Cialis, from Eli Lilly, is a phosphodiesterase type 5 inhibitor, in the same class as sildenafil (Viagra, Pfizer). The studies presented by Dr. Padma-Nathan did not compare the two drugs. "Cialis has a much longer duration than Viagra," said Dr. Irwin Goldstein, MD, professor of surgery at Boston University. He admitted that the length of duration may be a benefit of Cialis, in that couples can expect to engage in intercourse more than once on each dose of the drug over a substantial period. However, Goldstein said he was concerned that long-term suppression of tightly regulated functions involved in erections might have long-term problems. He said not enough data existed to indicate whether there is a potential problem in this area; nor is there data to prove it is not going to be a problem.
|
